Case reports and small case series have documented successful treatment of ICI-related myocarditis with various agents, including intravenous immunoglobulin (160), mycophenolate (161), infliximab (anti-TNF mAb) (162), anti–thymocyte globulin (145), plasmapheresis (162), alemtuzumab (anti-CD52 mAb) (163), and abatacept (CTLA-4 agonistic mAb) (164). The gene discussed is CTLA4; the disease is myocarditis.